Clinical-grade manufacturing for animal health — designed for USDA, EMA, and CVM compliance.

Introduction: The Veterinary Biologics Landscape

The global animal health industry is expanding rapidly, driven by pet care, livestock productivity, aquaculture, and zoonotic disease control. Whether producing vaccines for companion animals, therapeutic enzymes for livestock, or antibodies for aquaculture, veterinary biologics require the same rigor as human biologics — but with added complexity across multi-species pathways, diverse regulatory frameworks, and unique formulation requirements.

At MycoVista Veterinary Biologics CDMO Solutions, we apply the same Design → Data → Decision → GMP framework that underpins our therapeutic work, but tuned for the veterinary space. Our hub in San Diego provides quality systems, regulatory alignment, and resilience of supply, while our unified digital QMS (ALCOA+) guarantees that every batch is documented to inspection standards.

Animal health companies choose MycoVista because we understand the nuances of this sector: cost pressures in livestock vaccines, speed-to-market in aquaculture, and regulatory alignment with USDA, EMA, and CVM.

Programs We SupportSpecies-Specific Antibodies

Antibody therapeutics in veterinary medicine must respect interspecies immunobiology: Fc receptor repertoires differ, glycan preferences shift, and complement pathways vary across dogs, cats, horses, cattle, swine, poultry, small ruminants, and fish. What works in human CHO pipelines often fails in animals without re-engineering isotypes, hinge regions, and glycosylation to match the target species. Background strain immunity, maternal antibody interference (in neonates), and biodistribution across fur/feather/fat also matter. The keys are: (1) species-matched Fc backbones to tune ADCC/CDC, (2) glycan and charge control for comparability, (3) low endotoxin for parenteral routes, and (4) potency assays that reflect the animal’s biology, not a proxy cell line. MycoVista designs antibodies with these constraints up front, using CHO/HEK or microbial with refold/secretion options and analytics that tie structure to function so every lot behaves the same in clinic and field.

• Monoclonals & fragments for dogs, cats, horses, cattle, swine, poultry, small ruminants, fish (± camelids/exotics).
• Expression routes: CHO/HEK (fed-batch/perfusion), microbial with refold/secretion; Fc-engineering & species-matched isotypes.
• QC & release: species binding/neutralization, ADCC/CDC, glycan/charge windows, low-endo specs for injectables.

Therapeutic Enzymes

Veterinary enzyme therapy spans digestive support, metabolic correction, anti-inflammatory pathways, and rare disease interventions in companion and production animals. Unlike human use, physiologies vary widely: ruminant foregut conditions (pH ~6–7, high protease), monogastric GI (acidic stomach, bile salts), avian crop/gizzard dynamics, and aquatic environments (temperature/salinity gradients). Successful products require (1) an expression route that yields active enzyme at scale, (2) DSP that removes HCP/DNA and controls endotoxin to route-specific limits, (3) formulation that shields activity through transit and administration, and (4) potency assays built under species-relevant pH/ionic/protease backgrounds.

MycoVista engineers enzymes for stability and activity first, then locks a control strategy—so labeled activity holds from plant to paddock.

• Recombinant enzymes for digestion, metabolic support, inflammatory/genetic indications.
• Physiology-aware validation: activity/stability profiled at species-specific pH, temperature, protease milieu.
• Endotoxin-controlled DSP: robust HCP/DNA clearance, <EU/mg by route; oral, SC/IM, intraruminal formats.

Vaccines

Animal health vaccines must balance rapid prototyping, scalable expression, adjuvant compatibility, and lot-to-lot antigen fidelity—while withstanding rugged distribution to farms, hatcheries, kennels, and aquatic sites. Platform choice matters: microbial subunits for cost and speed, BEVS for complex antigens and glycoproteins, and viral vectors for strong cellular responses. Critical elements include (1) fast vectoring and expression with predictable yields, (2) orthogonal polishing to clear host impurities, (3) validated adjuvant pairing without potency loss, (4) stability under field-realistic temperatures, and (5) comparability windows that keep scale/supplier changes file-able.

MycoVista builds vaccine programs with these constraints pre-wired, so PPQ reads like execution—not discovery.

• Platforms: microbial subunits, viral-vector constructs, BEVS (Sf9/Sf21/High Five).
• Pathway: rapid baculovirus vectoring → high-yield expression → orthogonal DSP; adjuvant compatibility proven.
• Consistency: antigenicity, glycosylation, charge, and potency held within prespecified equivalence windows.

Oral & Injectable Formulations

Route of administration defines success in veterinary markets. Oral products must survive feed manufacturing, storage, and GI transit (rumen retention, gastric acidity, bile, proteases). Chewables require palatability without destabilizing actives. Injectables demand sterility assurance, low particulates, tight headspace O₂ control, and container-closure integrity in dusty, variable-temperature environments. The essentials: (1) formulation tuned to species route and husbandry workflow, (2) stress testing across vibration, thermal cycles, light, and humidity, (3) validated reconstitution and dose uniformity, and (4) aseptic fill–finish with CCIT and visual inspection that mirrors real handling. MycoVista designs formulations that behave in the plant—and on the farm.

• Presentations: oral suspensions, feed premixes, palatable chewables, oil-in-water emulsions, injectables.
• Stress testing: rumen/intestinal fluids; aquatic media (fresh/salt/brackish); vibration/thermal transit.
• Fill–finish: aseptic vialing, prefilled syringes; headspace O₂ targets, CCIT, label-claim via regression.

Regulatory Alignment

Veterinary biologics span three authorities and divergent expectations: USDA CVB (vaccines/antitoxins/diagnostics), EMA/CVMP (EU animal health biologics), and FDA CVM (therapeutic proteins, enzymes, novel modalities). Winning submissions share traits: dossiers that mirror the floor, potency justified by species-relevant assays, validation sized to risk, and prespecified comparability for scale or supplier changes. MycoVista architects programs to meet this triad from day zero—so audits confirm what the batch records already prove.

• USDA CVB: vaccine/antitoxin/diagnostic pathways; field-realistic stability and validated potency.
• EMA/CVMP: EU dossiers with comparability, pharmacovigilance planning, and quality lifecycle.
• FDA CVM: therapeutic proteins/enzymes; full CMC, validation, and CPV plans tied to real process controls.

MycoVista Veterinary Biologics CDMO Solutions provides:

Audit confidence: ALCOA+ integrity, review-by-exception, and PAI/mock-inspection playbooks tailored per species & route.

Dossier authorship & mapping aligned to USDA, EMA, CVM; Modules/sections reflect actual plant logic.

Executable records: inspection-ready SOPs, digital eBMR/eBR, batch/QC packages, pre-filed comparability.

Challenges in Veterinary Biologics & How We Solve Them

1. Multi-Species Complexity

Each species has unique immunology, metabolism, and dosage requirements.

• Our solution: Species-specific QC assays and formulations designed to match physiological environments.

2. Cost Pressure in Livestock

Margins in livestock vaccines are tighter than in human health.

• Our solution: High-yield microbial expression, intensified DSP, and scalable stainless runs up to 50,000 L.

3. Regulatory Diversity

Navigating USDA, EMA, and CVM simultaneously can be costly and time-consuming.

• Our solution: Unified digital QMS with parallel documentation packages that can be tailored per regulator.

4. Field Trial Supply

Veterinary programs often require mid-scale supply for geographically dispersed field trials.

• Our solution: Flexible pilot → mid-scale → GMP supply with logistics-ready labeling and documentation.

Program Flow

1. Technical Deep-Dive – Define species, target, modality, and regulatory path.
2. Proposal – Scope, cost, and timeline aligned to USDA/EMA/CVM requirements.
3. QA Access – Optional pre-award audits with full quality transparency.
4. Onboarding (30 Days):
   • QTPP/CQA map for species-specific needs.
   • Draft control strategy.
   • DoE plan for fermentation/vaccine optimization.
   • Gantt + FMEA for field trial readiness.
5. Design → Data – PAT-monitored runs, weekly updates, variance reports.
6. Decision Gate – Advance only when manufacturability, cost, and regulatory compliance are validated.

Analytics First

At MycoVista Biotech, data defines durability. Every veterinary biologic—whether a recombinant enzyme, vaccine, or antibody—lives or dies by the quality of its analytical evidence. Our San Diego facility runs a complete, species-aware analytical suite built to global regulatory expectations (USDA CVB, EMA CVMP, CVM). We treat each program as an independent control strategy, from potency through stability to comparability.

We design and validate potency assays specific to each target species—canine, feline, equine, bovine, porcine, ovine, avian, piscine, and even camelid or exotic species—using primary or immortalized cell lines that reproduce field physiology. For veterinary vaccines, we perform neutralization, hemagglutination-inhibition, and ELISA-based potency studies with appropriate reference standards. For therapeutic enzymes and antibodies, we tailor species-specific binding and activity assays that correlate potency with pharmacodynamic relevance.

Stability testing covers every climatic and logistical reality—accelerated, real-time, and in-use conditions with humidity, freeze–thaw, and vibration stress. Data are analyzed by regression with confidence bounds so label-claim shelf life is not a guess but a statistical decision.

Our glycan and charge-variant profiling (HILIC UPLC, icIEF, CE-SDS, MS) ensures comparability across sites, scales, and manufacturing changes. We provide orthogonal impurity and residuals analysis—host-cell protein/DNA quantification, endotoxin (LAL/KTA), and bioburden trending—especially for parenteral veterinary therapeutics where pyrogen control is critical. For recombinant vaccines, antigen integrity and particle morphology are tracked by DLS and EM to confirm dose reproducibility.

We also maintain dedicated immunogenicity screening workflows, including serum antibody response monitoring and cytokine-release panels for new adjuvant systems. All assays operate within our unified digital QMS (ALCOA+), ensuring traceability from raw signal to Certificate of Analysis.

Facilities & Scale

MycoVista’s Veterinary Biologics CDMO infrastructure in San Diego is configured for both microbial and mammalian modalities, ensuring rapid transition from development to GMP production.

• Microbial & Fungal Systems: Bench → pilot → 50,000 L stainless (validated CIP/SIP). Hosts include E. coli, Bacillus, Corynebacterium, Aspergillus, Pichia, and Kluyveromyces. We support subunit antigens, enzymes, and vaccine carriers, with O₂ enrichment and methanol envelopes where productivity demands it.
• Mammalian Cell Culture: 50 L / 250 L single-use suites scaling to multi-thousand-liter perfusion for mAbs, Fc-fusions, and veterinary cytokines. Perfusion and fed-batch options are validated for clonality, stability, and consistent glycosylation across lots.
• BEVS (Insect Platform): Rapid virus expansion in Sf9, Sf21, High Five cell lines for subunit and whole-virion veterinary vaccines. Integrated clarification and capture workflows yield field-ready antigen with minimal purification cycles.
• Formulation & Fill–Finish: Aseptic vialing, prefilled syringes, chewable or oral formulations, and liquid suspensions designed for on-farm dosing or feed integration. Lyo and spray-dry cycles are qualified for moisture and potency retention.
• Cleanrooms & Utilities: ISO 8/7 suites with validated HPW, clean steam, and compressed air; pressure cascades and unidirectional flow engineered for sterility assurance. Environmental monitoring follows Annex 1 and CVB Guideline 8008 protocols.

Representative Case Studies

Avian Diagnostics Panel: Multiplex antigen production in E. coli with ISO 13485 documentation; delivered as lyophilized reagents for hatchery monitoring systems.

Livestock Vaccine: Recombinant antigen expressed in Corynebacterium glutamicum, scaled to 20,000 L with antigenicity drift < 2 %; dossier compiled and accepted by USDA CVB.

Canine Antibody Therapeutic: CHO expression of bivalent IgG; potency verified through canine-specific ELISA and ADCC assays; CVM submission prepared with full CMC section.

Aquaculture Vaccine: BEVS-derived viral subunit optimized for potency in marine and freshwater species; stability qualified at 10 °C; 10-week turnaround to field-trial supply.

Equine Enzyme Therapy: Pichia pastoris fermentation, refold and purification; endotoxin < 0.05 EU/mg; stability maintained for 24 months; EMA CVMP dossier in progress.

Why Teams Choose MycoVista Veterinary Biologics CDMO Solutions

• Species-specific expertise: Antibodies, enzymes, vaccines across multiple animals.
• Regulatory strength: Dossier-ready packages for USDA, EMA, CVM.
• Scale flexibility: Bench → mid-scale → field trial → commercial.
• Analytics-first: Potency, stability, comparability locked early.
• Dual-hub resilience: San Diego & Montréal mirrored quality and capacity.

Conclusions

Animal-health biologics succeed only when three things align: precision analytics, regulatory fluency, and manufacturability across species and routes. At MycoVista Veterinary Biologics CDMO Solutions, we deliver all three—end to end—so your antibody, enzyme, or vaccine behaves the same in dossier, clinic, and field. Our San Diego operation integrates microbial, mammalian, and BEVS platforms with an ALCOA+ digital QMS, locking QTPP→CQA→CPP control strategies into executable eBMR recipes, guardbands, and interlocks. We author USDA CVB, EMA CVMP, and FDA CVM packages that mirror the floor, then validate what matters: potency by species, endotoxin and bioburden for parenterals, glycan/charge windows for comparability, and stability that survives rumen, GI, hatchery, or aquatic conditions.

Scale is a decision, not a gamble: bench → pilot → 50,000 L stainless for microbial programs, 250 L single-use mammalian suites to multi-kL perfusion, and rapid BEVS lines for vaccine speed. PPQ runs prove capability (Cp/Cpk) before reports close, CPV dashboards make drift obvious, and pre-filed comparability keeps supplier or formulation changes file-able—so launch timelines hold. As the best veterinary partner in California, we also bring hard-won lessons from adjacent modalities—our leadership in Exosome CDMO analytics, formulation, and aseptic operations further sharpens your risk profile. When your pipeline expands into vesicle-based delivery for animal health, you already have the state-of-the-art Exosome CDMO infrastructure behind you.

If you need a veterinary CDMO that builds manufacturability by default—and stands in front of the data—choose MycoVista. We take programs from design to GMP, without detours, and all the way to commercial reality.

Contact info@mycovistabiotech.com today to accelerate your veterinary biologics!

Learn more about our –> Exosome CDMO Services